Hans Hofland

Hans Hofland is a researcher in the Department of Internal Medicine at Erasmus MC, a leading academic medical center in the Netherlands. His work is centered on endocrinology and oncology, particularly in the field of neuroendocrine tumors and radionuclide therapies.

• Institution: Erasmus MC
• School: Faculty of Medicine
• Department: Department of Internal Medicine
• Position: Researcher

Dr. Hofland’s research focuses on peptide receptor radionuclide therapy (PRRT), neuroendocrine tumors, and endocrine oncology. His work spans clinical trials, treatment guidelines, diagnostic imaging, and biomarker evaluation. He actively contributes to national and international consensus efforts, including those led by the European Neuroendocrine Tumor Society (ENETS).

His recent publications highlight expertise in PRRT using agents like [177Lu]Lu-DOTA-TATE and [177Lu]Lu-PSMA-I&T, patient selection, response evaluation, renal protection, and outcomes in diverse populations including elderly patients and those with metastatic disease. The body of work reflects a strong emphasis on real-world evidence, multicentre collaboration, and translational research.

Dr. Hofland has contributed to over 130 research outputs, including original articles, reviews, and chapters. His work frequently appears in high-impact journals such as Journal of Neuroendocrinology, European Journal of Nuclear Medicine and Molecular Imaging, and Endocrine-Related Cancer.

He has supervised doctoral theses and mentored junior researchers, contributing to academic training in endocrinology and nuclear medicine. While no specific grants are listed, his involvement in large-scale, multi-institutional studies suggests participation in funded research programs.

Dr. Hofland is affiliated with a robust clinical and research network in endocrinology, collaborating with experts across Europe. His work supports the advancement of theranostics in oncology and improves clinical management of complex endocrine disorders.